ReviewEuropean respiratory review : an official journal of the European Respiratory Society2016
Epigenetic mechanisms in pulmonary arterial hypertension: the need for global perspectives.
Review in European respiratory review : an official journal of the European Respiratory Society, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 51 citations in OpenAlex.
- Pulmonary Arterial Hypertension: Reconfiguring the Vascular Landscape to Reverse Remodeling.Cells · 2026Article
- Emerging Technologies for Exploring the Cellular Mechanisms in Vascular Diseases.International journal of molecular sciences · 2025Review
- DNMT1 deficiency promotes pulmonary vascular remodeling in pulmonary hypertension through epigenetic upregulation of BMP7.Respiratory research · 2025Article
- Review
- Review
- Unraveling the role of HIF and epigenetic regulation in pulmonary arterial hypertension: implications for clinical research and its therapeutic approach.Frontiers in medicine · 2024Review
- Unraveling the epigenetic landscape of pulmonary arterial hypertension: implications for personalized medicine development.Journal of translational medicine · 2023Review
- MicroRNA and lncRNA as the Future of Pulmonary Arterial Hypertension Treatment.International journal of molecular sciences · 2023Review
- Histone Methyl Transferase G9a/GLP-A Novel Avenue in Pulmonary Arterial Hypertension Treatment?American journal of respiratory cell and molecular biology · 2023Article
- Epigenetic regulation of programmed cell death in hypoxia-induced pulmonary arterial hypertension.Frontiers in immunology · 2023Review
- Pharmacological Inhibition of Lysine-Specific Demethylase 1A Reduces Atherosclerotic Lesion Formation in Apolipoprotein E-Deficient Mice by a Mechanism Involving Decreased Oxidative Stress and Inflammation; Potential Implications in Human Atherosclerosis.Antioxidants (Basel, Switzerland) · 2022Article
- Future Perspectives of Pulmonary Hypertension Treatment.Acta Cardiologica Sinica · 2022Review
- Perillyl alcohol and quercetin modulate the expression of non-coding RNAs MIAT, H19, miR-29a, and miR-33a in pulmonary artery hypertension in rats.Non-coding RNA research · 2022Article
- Mechanisms Contributing to the Dysregulation of miRNA-124 in Pulmonary Hypertension.International journal of molecular sciences · 2021Article
- Non-Coding RNA Networks in Pulmonary Hypertension.Frontiers in genetics · 2021Review
- Epigenetic Targets for Oligonucleotide Therapies of Pulmonary Arterial Hypertension.International journal of molecular sciences · 2020Review
- Adaptive and innate immune mechanisms in cardiac fibrosis complicating pulmonary arterial hypertension.Physiological reports · 2020Review
- Cancer and pulmonary hypertension: Learning lessons and real-life interplay.Global cardiology science & practice · 2020Review
- DNA Methylation and Histone Modification in Hypertension.International journal of molecular sciences · 2018Review
- FOXM1 promotes pulmonary artery smooth muscle cell expansion in pulmonary arterial hypertension.Journal of molecular medicine (Berlin, Germany) · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary arterial hypertension (PAH) is a severe and progressive disease, characterised by high pulmonary artery pressure that usually culminates in right heart failure. Recent findings of alterations in the DNA methylation state of superoxide dismutase 2 and granulysin gene loci; histone H1 levels; aberrant expression levels of histone deacetylases and bromodomain-containing protein 4; and dysregulated microRNA networks together suggest the involvement of epigenetics in PAH pathogenesis. Thus, PAH pathogenesis evidently involves the interplay of a predisposed genetic background, epigenetic state and injurious events. Profiling the genome-wide alterations in the epigenetic mechanisms, such as DNA methylation or histone modification pattern in PAH vascular cells, may explain the great variability in susceptibility and disease severity that is frequently associated with pronounced remodelling and worse clinical outcome. Moreover, the influence of genetic predisposition and the acquisition of epigenetic alterations in response to environmental cues in PAH progression and establishment has largely been unexplored on a genome-wide scale. In order to gain insights into the molecular mechanisms leading to the development of PAH and to design novel therapeutic strategies, high-throughput approaches have to be adopted to facilitate systematic identification of the disease-specific networks using next-generation sequencing technologies, the application of these technologies in PAH has been relatively trivial to date.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.